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Background: Fluralaner (Bravecto™; Merck/MSD Animal Health) is a novel systemic ectoparasiticide for dogs
providing long-acting flea and tick control after a single oral dose. Milbemycin oxime and praziquantel are routinely
used to control Dirofilaria immitis and intestinal worm infections in dogs. The safety of concurrent use of fluralaner
and a commercially available milbemycin oxime plus praziquantel combination tablet, in particular with regard to
gastrointestinal symptoms, was investigated using oral doses at or above the maximum recommended rates.
Findings: Some minor and transient clinical findings were observed during the study period; however, none of
these was considered to be related to concurrent treatment with fluralaner and milbemycin oxime plus
praziquantel, or to the use of either product alone.
Conclusions: Concurrent treatment with fluralaner, milbemycin oxime and praziquantel is well tolerated in dogs.
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Fluralaner (Bravecto™; Merck/MSD Animal Health) is a
systemically administered insecticidal and acaricidal
product. Numerous studies including a recent field
study in dogs have shown that a single fluralaner dose
administered orally as chewable tablet provides flea
and tick control for twelve weeks [1].
Milbemycin oxime is active against larval and adult
stages of intestinal nematodes as well as against larval
blood stages of heartworm (Dirofilaria immitis). Prazi-
quantel is active against cestodes and trematodes [2,3].
Dogs may concurrently be exposed to tick and flea
infestations, heartworm infestations and intestinal worm
infestations, therefore veterinarians may choose to admin-
ister fluralaner concurrently with milbemycin oxime and
praziquantel. For both products mild and transient gastro-
intestinal effects, like vomiting, inappetence, drooling and
diarrhea, may occur after oral administration [2-4]. To
confirm the safety of the concurrent use of fluralaner and
milbemycin oxime plus praziquantel, in particular with* Correspondence: feli.walther@msd.de
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unless otherwise stated.regard to gastrointestinal symptoms, a study was conducted
in healthy dogs. Fluralaner tablets (Bravecto™) and a com-
mercially available milbemycin oxime plus praziquantel
combination tablet were orally administered at or above
the recommended treatment dose (recommended treat-
ment dose: 25–56 mg/kg BW for fluralaner, 0.5 - 5 mg/kg
BW for milbemycin oxime, 5–50 mg/kg BW for prazi-
quantel) [2-4].Methods
The study was conducted in Queensland, Australia,
with the authorization of relevant regulatory authorities
(Queensland Department of Agriculture, Fisheries and
Forestry, approval no. CA 2014/05/768).
Twenty healthy male and female dogs of various breeds,
1.4 – 8.6 (mean 5.3) years of age and weighing 5.8 – 33.9
(mean 21.6) kg, were randomly assigned to two study
groups. Dogs were acclimatized for 7 days before treatment.
On day 0, dogs of the treatment group were administered
fluralaner chewable tablets and commercially available
milbemycin oxime plus praziquantel combination tablets.
Dogs of the control group received the milbemycin oxime
plus praziquantel combination tablets only.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Doses of fluralaner, milbemycin oxime and praziquantel administered to dogs of the treatment and control
group
Active ingredient (mg/kg) Treatment group Control group
Dose range Mean dose Dose range Mean dose
Fluralaner 50 – 87 64 - -
Milbemycin oxime 2.6 – 4.4 2.9 2.5 – 4.1 2.8
Praziquantel 26 – 44 29 25 – 41 28
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groups are presented in Table 1. Dogs in both groups
were fed directly before treatment as recommended on
the product leaflets [2-4].
Dogs of both groups were observed for general health
during the first hour following treatment and were ex-
amined by a veterinarian at 2, 3, 4, 5, 6, 9, 12, 24, 36, 48,
60, 72 and 84 hours, and 4, 5, 6 and 7 days after treat-
ment. The veterinarian examined for abnormalities in
behavior, locomotion, coat and skin, respiration, eyes,
ears, nose, oral cavity, mucous membranes, capillary re-
fill time, pulse palpation, vomitus, feces and urine as
present in pen, and any other visible abnormalities.
Veterinary examinations continued on study days 16
and 28 (examinations included assessment of abnor-
malities in behavior, locomotion, auscultation of heart
and thorax, heart rate, respiratory rate, pulse palpation,
mucous membranes, capillary refill time, abdominal
palpation, superficial lymph nodes, skin, eyes, pupils,
ears, nose, mouth, teeth, tongue, anus, vagina, penile
orifice, mammary glands, testicles, joints, feet, pads,
rectal temperature, body condition) and general health
observations of dogs in their pen were performed twice
daily at least 6 hours apart. The veterinary study inves-
tigator assessed all parameters recorded and all clinical
findings for their relationship to treatment with flura-
laner and/or with the milbemycin oxime plus praziquantel
combination product. Body weights were recorded
weekly.Table 2 Clinical findings in the treatment and control group p
Num
Trea
Single small and mild skin lesions (scar/papilloma/sore
spots/alopecia/erythema/laceration/graze/scab/scaling)
4
Small amount of serous eye discharge 2
Sinus arrhythmia 1: da
Loose feces with normal feces 1: da
Others 1 exc
*None of these observations was considered to be treatment related, because a sim
pre-treatment and/or the long interval between treatment and occurrence. All obse
**None of these observations was considered to be treatment related, because the
dog colony.Results and discussion
Throughout the 4-week study period, there were no
findings related to the concurrent treatment with flurala-
ner and milbemycin oxime plus praziquantel (treatment
group), or to the treatment with milbemycin oxime plus
praziquantel (control group).
Dogs were in the fed status when treated ensuring
maximum systemic exposure to fluralaner [5]. Clinical
observations were scheduled to cover the period of
highest systemic exposure to milbemycin oxime, prazi-
quantel [2,3] and fluralaner [6]. Therefore, clinical signs
associated with the concurrent use, e.g. gastrointestinal
symptoms, would most likely be apparent at these time
points. However, no vomiting, diarrhea, drooling or
other clinical signs were observed in any dog during the
first hour of clinical observation or during the frequent
veterinary examinations performed over the first days
following treatment. Occasional clinical findings were
observed in individual dogs from the treated and con-
trol group during the study (Table 2). Clinical findings
included incidences of single small and mild skin lesions
(both groups; includes scar, papilloma, sore spots, alopecia,
erythema, laceration, graze, scab, scaling), small amounts of
serous eye discharge (both groups), excess ear wax (treated
group), dental tartar (both groups), penile discharge (con-
trol group), transient limping immediately post-treatment
(control group), sinus arrhythmia (both groups; single event
in the treated group 28 days post-treatment) and loose
feces with normal feces (treated group; single event 7 daysost-treatment
ber of dogs affected
tment group* Control group**
7
1
y 28 (1: day −7)
y 7 0
ess ear wax, 2 dental tartar 1 penile discharge, 1 dental tartar,
1 transient limping
ilar incidence occurred in the control group, they were already observed
rvations were common findings in a dog colony.
y were already observed pre-treatment and/or are common findings in a
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both groups, and none affected the general health condi-
tion of dogs. The observations in the treated group were
considered to be unrelated to the concurrent treatment
with fluralaner and milbemycin oxime plus praziquantel
or to the use of either product alone, because a similar in-
cidence occurred in the control group, they were already
observed pre-treatment and/or the long interval between
treatment and observation. All observations were con-
sidered to be common findings in a dog colony. The
observations in the control group were considered to
be unrelated to the treatment with milbemycin oxime
plus praziquantel, because they were already observed
pre-treatment and/or are common findings in a dog
colony.
There were no obvious changes in group mean body-
weights during the study (mean body weights for the
treatment group were 21.3 kg pre-treatment and
22.1 kg at study end, and for the control group 21.9 kg
pre-treatment and 22.6 kg at study end).
These results are consistent with previous data showing
no evidence for interactions of Bravecto™ with other
routinely used veterinary medicinal products [3,7].
Conclusion
Concurrent treatment with fluralaner, milbemycin oxime
and praziquantel is well tolerated in dogs.
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